{"name":"Kite, A Gilead Company","slug":"kite-a-gilead-company","ticker":"","exchange":"","domain":"kiteagileadcompany.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"KITE-197","genericName":"KITE-197","slug":"kite-197","indication":"Other","status":"phase_2"},{"name":"KITE-363","genericName":"KITE-363","slug":"kite-363","indication":"Other","status":"phase_2"},{"name":"KITE-753","genericName":"KITE-753","slug":"kite-753","indication":"Relapsed or refractory B-cell malignancies (Phase 3 development)","status":"phase_3"},{"name":"KTE-X19","genericName":"KTE-X19","slug":"kte-x19","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Anitocabtagene autleucel","genericName":"Anitocabtagene autleucel","slug":"anitocabtagene-autleucel","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"},{"name":"Platinum-containing Salvage Chemotherapy","genericName":"Platinum-containing Salvage Chemotherapy","slug":"platinum-containing-salvage-chemotherapy","indication":"Relapsed or refractory lymphoma (salvage therapy)","status":"phase_3"}]}],"pipeline":[{"name":"KITE-197","genericName":"KITE-197","slug":"kite-197","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Anitocabtagene autleucel","genericName":"Anitocabtagene autleucel","slug":"anitocabtagene-autleucel","phase":"phase_2","mechanism":"Anitocabtagene autleucel is a chimeric antigen receptor (CAR) T-cell therapy that targets the B-cell maturation antigen (BCMA) on multiple myeloma cells.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"KITE-363","genericName":"KITE-363","slug":"kite-363","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"KITE-753","genericName":"KITE-753","slug":"kite-753","phase":"phase_3","mechanism":"KITE-753 is a CAR-T cell therapy that redirects a patient's own T cells to recognize and kill cancer cells expressing a specific tumor antigen.","indications":["Relapsed or refractory B-cell malignancies (Phase 3 development)"],"catalyst":""},{"name":"KTE-X19","genericName":"KTE-X19","slug":"kte-x19","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Platinum-containing Salvage Chemotherapy","genericName":"Platinum-containing Salvage Chemotherapy","slug":"platinum-containing-salvage-chemotherapy","phase":"phase_3","mechanism":"Platinum-containing chemotherapy agents work by forming DNA adducts that cross-link DNA strands, preventing replication and transcription, thereby inducing cancer cell death.","indications":["Relapsed or refractory lymphoma (salvage therapy)","Other platinum-sensitive malignancies in salvage setting"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOU0dEOHZCLWtoV241VDNvN1lUc3IxbURhVnl0QWdpenU2ZnA3Y3UwcDc4dk1LT3ctTG42eDd0SXdVZzZUb3psbDN4aldYYWdpaC1DdXd4QzJybHpWU1JoMmtxZXNJcEZpd0xBbWlFaE5nLW5hLU5idHFyMkFOUXo1dExJWXBqaEQweC1DOTNQcXRyMVd5NlhLSDdJeDY1aDNHSTRVanE0YWIwZzQzMVNvdUdLZEliT2s?oc=5","date":"2026-03-30","type":"pipeline","source":"Fierce Pharma","summary":"BMS, Novartis, Gilead, Iovance dinged over biologics promos in rare spate of CBER untitled letters - Fierce Pharma","headline":"BMS, Novartis, Gilead, Iovance dinged over biologics promos in rare spate of CBER untitled letters","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNeHFKZnB0ZURwWWhDam9ndFJiMmVLRkJFeGRyQnBycUFjOXFSc0toS1FSbWN2eXc4YkxwamJ1eUFNTkh1VGRNOC1LUWRZenhCT1NfMkZNMXJyZWlfbmxROURpSUNnTFdlSWs2MVZGeG5tRjFuQUNxSC1ORTducE9UMV9CQlRlRWU2UnozX2NGZC3SAZYBQVVfeXFMTnZqWDdTa0pQR0JXSnVLdzdiU2ZPRWRjOTRGRVJOOS1UVk0yRTl6Q1Z4Q1Q5VVRwUDhDWnVfQTNPak5JUk4zb3lQMHp5WXMxemVNNUljRDhKUzlucEl1RFd0dzdTeUEtUEdCWmdQZzZnQ01rbUJ0SEVpaGNWU0x2ZDRlS2lpZnNsdTh4Q1NRSm12MDhtNnF3?oc=5","date":"2026-02-23","type":"deal","source":"CNBC","summary":"Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion - CNBC","headline":"Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPS2NjdlNreDBiUlFVd1dQNHZUbldHVDBWZUJRUTd2d2ZNRFBYcUV3ZzBzZ1laTWJIMFdtc0xZVm0yUndxVVQyZHBLekpUaEVuRFBvQ1RVSWtQNk8xY0M4U2VmZHhfNVVhdzZQdEZNanlmdkJxWTFoc01fWHZ0Wm9SOXB4V0M5ZTNQQXpzeEh6SFdwc1cxdEg5cVJVNA?oc=5","date":"2026-02-12","type":"pipeline","source":"Pharma Voice","summary":"Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift - Pharma Voice","headline":"Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTFA4MW1uWXFaMEZKWnVLS2Uxb3pDNDNWaGdKcEdOZk5DVGNkNC1MMW5YWnQ4aGtOUnN3NEVCUEdST01POVBVbWFTSHI3SW5sbzA5NnduUk1DX056eXJyMU5HTU12d9IBaEFVX3lxTE1RSTBaZ0FBWTZoWUVHZ05NUktLTmxwVFFxRFQwRDRCWWRRTUlxa2R1c3VlS2hwZU9KVmFIU2t6ZExqMmFHOHZEc3NCbjFrbnQzQjNYMWdHRXoxNlhUN201N0RIenh3b0Jz?oc=5","date":"2026-02-09","type":"pipeline","source":"BioInformant","summary":"Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering - BioInformant","headline":"Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTFBoZWw2dFVDanRVQlFjc2J2YUkxWExrcnhUUVV1UWdxakx2endPZzlzWkpDS3BpV1NMRDItVk5yaUFFUVdPY3dSVFZuWFVXVUZOQ3VaQ0FPSk5wUVE?oc=5","date":"2026-01-30","type":"pipeline","source":"Oncodaily","summary":"Daniel O’Day: Turning Innovation Into Impact With Gilead Sciences and Kite Pharma Teams - Oncodaily","headline":"Daniel O’Day: Turning Innovation Into Impact With Gilead Sciences and Kite Pharma Teams","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOV19ZdWVxU29IUlZ4aDdHcUs3eGdqVk9jb2ZodHFxQW1FQWx4c3IyQ3FubkZkNmhQQzNlb0RIZzI3RUF4cUF2QU5DenpuLUhUenZnSmoxaWxQX0xTa1JuZ2RMbkxpOTRoUG11ZjdZSWwwd0tFUGhEUlBORm1oMk9WQ25sc09rel9uX1IzQVdVZHFqSUhBVEV5SjNKYmRSekZyeEdGNQ?oc=5","date":"2025-12-07","type":"pipeline","source":"Fierce Biotech","summary":"ASH: Anito-cel strengthens best-in-class potential as Gilead's Kite preps for launch - Fierce Biotech","headline":"ASH: Anito-cel strengthens best-in-class potential as Gilead's Kite preps for launch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPcUdNWDA2bVhCdzY3THRzV2Q3NjNNMkNWbXpsbk42RThsLU9RWTFqb3dnbzA2SFBpTGJEN2plLXN0MDBpQWFSQTNLUzRyWUhSOGlDTWhqOF9DV2ZzN1FVSmUxRmExSVBkd3RsLUxzczFIeUkwcFJoeDhGa19hcmxKb2R5TWR5ZTE3bWt5WV9RSDhUalRaQ0s4N3V0SDJlaFdJanc?oc=5","date":"2025-10-17","type":"pipeline","source":"BioSpace","summary":"Kite Makes $1.5B+ Cell Therapy Pact With Pregene as Others Pull Back - BioSpace","headline":"Kite Makes $1.5B+ Cell Therapy Pact With Pregene as Others Pull Back","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxPWml4YjB4d29LZlg2WkkwWVB2bEZQYWttSW82ejFIN2VuRGpMeTlETXpxVm5HX0ExVkxkRU9XWUJRcTFVNVV1bmNzWDdQZzM4cV9VVmRqSzVPcnZhaHFVNENrdXhwVUhxS1FGd3FZQUtxdVA4LVFjaG84YVJVQlh4RjRNMnNBUnhRVVdpeldNREVaUUJUMWtHeUJkQklMMUl2czM4RzRjdWVFSEVScXE1ZGN5TS1MZ0lxaDJleGw1eWxGUW83dmMyOEtNNkVKWmJWSVE?oc=5","date":"2025-08-22","type":"deal","source":"European Pharmaceutical Review","summary":"Gilead’s Kite agrees $350m deal to acquire US biotech Interius BioTherapeutics - European Pharmaceutical Review","headline":"Gilead’s Kite agrees $350m deal to acquire US biotech Interius BioTherapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOd0tfMEtPTWc5ZmhVMGh5N3RxTDl1VFVzaU4xUWRJVWNhb0EwRnR6Z0Y4R054eFdYV1RHc0tWODl3anpZSHg3VU5hLTdHYUpPdGNOLWozaWFJcjFEV3hNZ0lDc0szT1Nla201OXBYeEw3RjhhV2prQzBSbHk1aFRTSWEtRXFHWDV2dFVHVDZKSjY2VFVicDR1MHNvRG54eUE?oc=5","date":"2025-08-22","type":"deal","source":"Pharmaceutical Executive","summary":"Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million - Pharmaceutical Executive","headline":"Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQbld2T1REUGFQeUdJVWJDWmw4MmhpLXpUTTJHNDg4RDJIYjFySS1ERXF4UkgzY25sQjN0Y2o0Ni1JaENRbFJRNXFkZkl3RTNZY0pwLThHR005dDdtUVdENWdvTF9sUVJlZnMzVkVqaWJUQUJvRkYzOWFzWUswTzdYRE1IcEpGbEh5bXZFWkk2VjhUd2s?oc=5","date":"2025-08-21","type":"deal","source":"statnews.com","summary":"Gilead’s Kite Pharma acquires Interius BioTherapeutics for $350 million - statnews.com","headline":"Gilead’s Kite Pharma acquires Interius BioTherapeutics for $350 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPRkZZZm5xbFVzbjg1OHJZSDVRY0xlZnJSWWlIZG5vR05MZUVsS0VCTGVCcHF3ZHpGTnVoX0FhQloteUZFaWlEN3ozUDU4Tk1TSjUwNl8yNmp2dFJIa3JiaHZXRzRYWmVycGJNb2RXb0VKLTZiUEV4YzRfMkExQnZlOEJMY01lLUktbDNTUEFIN1hGUndWQ2ttZ25abjZTOVFWR0pWbU5yaVA0WWtOSnBhTXVuTVV5d1BDdDVCOWJsdFR0TW8?oc=5","date":"2025-08-21","type":"deal","source":"Business Wire","summary":"Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform - Business Wire","headline":"Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPVkFGaFhRTlR6ZVVsYWxyaEZxS0NNSzJYZ24tc1VMeFZHc2puUmU0VGNjczFURW1FX2FwYVV1NUlmNmZDYVB0bktscXY5TEJhVWthcmhveTVHcmZtN0RtLWJ0cFFDTDAwcjFWT0ZUSzdkMDluZFJtVklaRkNUUjI2bGxCTQ?oc=5","date":"2025-07-10","type":"pipeline","source":"WHYY","summary":"Layoffs hit Philly biotech startup after being bought by Big Pharma - WHYY","headline":"Layoffs hit Philly biotech startup after being bought by Big Pharma","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_2":4,"phase_3":2},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}